课题基金 / 基金详情

Neuroactive Steroids and Seizure Control during Pregnancy in Women with Epilepsy

Neuroactive Steroids and Seizure Control during Pregnancy in Women with Epilepsy
癫痫女性怀孕期间的神经活性类固醇和癫痫发作控制
批准号:
7921365
负责人:
Page Buckhannan Pennell
金额:
$10.18万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-01 至 2013-08-31

项目摘要

项目成果

Page Buckhannan Pennell的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):癫痫是一种常见的疾病,在美国大约有130万育龄妇女受到影响。怀孕期间的癫痫发作会增加母亲和胎儿的风险。这些风险必须与已知的抗癫痫药物(AED)的致畸作用进行权衡。在怀孕期间,性类固醇激素雌二醇和孕酮急剧增加。性类固醇激素和能够改变神经活动的代谢副产物被归类为神经活性类固醇(NAS)。动物模型显示NAS 17?-雌二醇(EST)、孕酮(PROG)和别孕酮(Allo)对癫痫发作活动有调节作用。在女性中,这些NAS的波动与非怀孕状态下的癫痫控制有关,在月经周期的某些时候癫痫发作加剧(月经性癫痫)。人体研究表明,随着EST/Prog比率的升高和Prog水平的下降或降低,癫痫发作频率增加。这在患有癫痫的妇女怀孕期间还没有被研究过。这项拟议的研究将利用在专门的妇女和性别问题研究中心项目赠款期间从135名怀孕不同阶段的癫痫患者身上收集的血清样本(n=810个样本)。这些妇女被前瞻性地登记跟踪癫痫发作和药物治疗。在每三个月的多个时间点采集血浆样本。基于可变点的登记(妊娠20周),我们增加了怀孕后三个月的观察/样本。将分析怀孕中期和晚期的癫痫发作频率,并与每个受试者的非怀孕基线进行比较。与R03机制一致,当前的应用程序将通过测量神经活性类固醇EST、PROG和ALLO来扩展对这些现有数据/样本的分析。工作假设是:1)妊娠期间,EST和PROG浓度的变化影响癫痫的控制;2)孕酮代谢产物ALLO介导了PROG的癫痫减轻作用。将分析以下几项与妊娠期癫痫发作频率变化的关系:Est/Prog比值、Prog升高速率和Allo升高速率。此外,考虑到分娩和分娩是癫痫发作增加的特别脆弱的时期;围产期癫痫发作的妇女和没有发作的妇女之间的Allo和Prog水平将进行比较。这项研究最终可以更好地理解NAS对妊娠期癫痫控制的调节。从这项研究中获得的见解可以为NAS类似物的进一步发展提供动力,治疗的好处延伸到两性和所有年龄段。在怀孕期间,补充孕酮可以降低胎儿在宫内接触AEDs的水平,改善癫痫发作控制,减少解剖和神经发育畸形。公共卫生相关性:治疗怀孕期间患有癫痫的妇女需要一种不稳定的平衡,既要控制母亲的癫痫发作,又不能让发育中的胎儿接触到超过必要的抗惊厥药物。怀孕期间,性激素及其代谢副产物的升高可能会直接影响癫痫的控制;这项研究将分析怀孕期间癫痫患者已经获得的血液样本,以检查癫痫发作增加的女性是否有神经活性类固醇水平的变化。这些发现可能导致为怀孕期间患有癫痫的妇女开发新的治疗策略,例如使用补充孕酮,以改善母婴健康结果。
英文摘要
DESCRIPTION (provided by applicant): Epilepsy is a common disorder, affecting approximately 1.3 million women of child-bearing age in the United States. Seizures during pregnancy can cause increased risks to both the mother and fetus. These risks have to be balanced against the known teratogenic effects of antiepileptic drugs (AEDs). During pregnancy, the sex steroid hormones estradiol and progesterone increase dramatically. Sex steroid hormones and the metabolic byproducts that are capable of modifying neural activity are classified as neuroactive steroids (NAS). Animal models demonstrate modulation of seizure activity by the NAS 17¿-estradiol (EST), progesterone (PROG), and allopregnanolone (ALLO). In women, fluctuations in these NAS have been implicated in seizure control in the non-pregnant state, with worsening seizures at certain times of the menstrual cycle (catamenial epilepsy). Human studies have demonstrated an increase in seizure frequency with elevated EST/PROG ratios and with declining or low PROG levels. This has not been studied during pregnancy in women with epilepsy. This proposed study will utilize serum samples (n=810 samples) already collected from 135 women with epilepsy during different stages of pregnancy during a Specialized Center of Research in Women and Gender Issues program project grant. These women were enrolled prospectively with tracking of seizures and medications. Collection of plasma samples occurred at multiple points in each trimester. Based on variable points of enrollment (< 20 weeks gestation), we have increased observations/samples in the later trimesters of pregnancy. Seizure frequency will be analyzed during the second and third trimesters of pregnancy and compared to the nonpregnant baseline for each subject. Consistent with the R03 mechanism, the current application will extend the analysis of these existing data/samples via measurement of the neuroactive steroids EST, PROG, and ALLO. The working hypotheses are 1) during pregnancy, changing concentrations of EST and PROG influence seizure control; 2) the progesterone metabolite, ALLO, mediates the seizure-reducing effect of PROG. The following will be analyzed in relationship to change in seizure frequency during pregnancy: EST/PROG ratio, the rate of rise of PROG, and the rate of rise of ALLO. Additionally, given that labor and delivery is a particularly vulnerable time for increased seizures; ALLO and PROG levels will be compared between women who had peripartum seizures and those who did not. This study can ultimately lead to a better understanding of the NAS regulation of seizure control during pregnancy. Insights gained from this study could provide the impetus for further development of NAS analogs, with treatment benefits extending to both genders and across all ages. During pregnancy, treatment with supplemental progesterone could allow for decreased levels of fetal exposure to AEDs in utero, with improved seizure control and reduced anatomical and neurodevelopmental teratogenicity. PUBLIC HEALTH RELEVANCE: Treating women with epilepsy during pregnancy requires a precarious balance of controlling the mother's seizures without exposing the developing fetus to more anticonvulsant medication than necessary. During pregnancy, the rising sex steroid hormones and their metabolic byproducts may directly influence seizure control; this study will analyze blood samples already obtained in women with epilepsy during pregnancy to examine whether women with increased seizures have alterations in neuroactive steroid levels. These findings could lead to the development of novel treatment strategies for women with epilepsy during pregnancy, such as use of supplemental progesterone, to improve mother and child health outcomes.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.ncl.2009.08.005
发表时间: 2009-11
期刊: NEUROLOGIC CLINICS
影响因子: 2.4
作者: [Pennell, Page B.]
通讯作者: Pennell, Page B.
DOI: 10.1016/s1474-4422(12)70239-9
发表时间: 2013-01
期刊: The Lancet. Neurology
影响因子: --
作者: [Harden CL, Pennell PB]
通讯作者: Pennell PB
Neuroactive Steroids and Seizure Control during Pregnancy in Women with Epilepsy
  • 批准号:
    7739995
  • 项目类别:
  • 资助金额:
    $10.26万
  • 财政年份:
    2009
  • 负责人:
    Page Buckhannan Pennell
  • 依托单位:
METABOLISM OF ANTIEPILEPTIC DRUGS
  • 批准号:
    7376373
  • 项目类别:
  • 资助金额:
    $0.84万
  • 财政年份:
    2005
  • 负责人:
    Page Buckhannan Pennell
  • 依托单位:
海外基金